Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Flow cytometry [2]
- Other assay [7]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15-0339-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD33 Monoclonal Antibody (HIM3-4), PE-Cyanine5, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The HIM3-4 monoclonal antibody reacts with human CD33, a 67 kDa member of the sialoadhesion family. CD33 is expressed by myelomonocytic precursors, monocytes, mast cells, and granulocytes. Hematopoietic stem cells and lymphocytes do not express this antigen. CD33 plays a role in sialic-acid dependent cell adhesion. Applications Reported: The HIM3-4 antibody has been reported for use in flow cytometric analysis. Applications Tested: This HIM3-4 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (1 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Light sensitivity: This tandem dye is sensitive photo-induced oxidation. Please protect this vial and stained samples from light. Fixation: Samples can be stored in IC Fixation Buffer (Product # 00-822-49) (100 µL cell sample + 100 µL IC Fixation Buffer) or 1-step Fix/Lyse Solution (Product # 00-5333-54) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically. Excitation: 488-561 nm; Emission: 667 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- HIM3-4
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4°C, store in dark, DO NOT FREEZE!
Submitted references Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Accumulation of T-helper 22 cells, interleukin-22 and myeloid-derived suppressor cells promotes gastric cancer progression in elderly patients.
Enhanced circulating ILC2s and MDSCs may contribute to ensure maintenance of Th2 predominant in patients with lung cancer.
Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.
Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S
Cell 2018 May 31;173(6):1439-1453.e19
Cell 2018 May 31;173(6):1439-1453.e19
Accumulation of T-helper 22 cells, interleukin-22 and myeloid-derived suppressor cells promotes gastric cancer progression in elderly patients.
Chen X, Wang Y, Wang J, Wen J, Jia X, Wang X, Zhang H
Oncology letters 2018 Jul;16(1):253-261
Oncology letters 2018 Jul;16(1):253-261
Enhanced circulating ILC2s and MDSCs may contribute to ensure maintenance of Th2 predominant in patients with lung cancer.
Wu Y, Yan Y, Su Z, Bie Q, Chen X, Barnie PA, Guo Q, Wang S, Xu H
Molecular medicine reports 2017 Jun;15(6):4374-4381
Molecular medicine reports 2017 Jun;15(6):4374-4381
Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.
Wang T, Li C, Xia C, Dong Y, Yang D, Geng Y, Cai J, Zhang J, Zhang X, Wang J
American journal of translational research 2015;7(10):1963-73
American journal of translational research 2015;7(10):1963-73
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with PE-Cyanine5 Mouse IgG1 K Isotype Control (Product # 15-4714-81) (open histogram) or Anti-Human CD33 PE-Cyanine5 (filled histogram).Cells in the monocyte gate were used for analysis.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with PE-Cyanine5 Mouse IgG1 K Isotype Control (Product # 15-4714-81) (open histogram) or Anti-Human CD33 PE-Cyanine5 (filled histogram).Cells in the monocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2. Flow cytometric analysis of MDSCs in peripheral whole blood from EGC (n=39), HE (n=32) and HY (n=31). Gating routine in (A) P1 and (B) P2 successively for MDSCs (HLA-DR - CD33 + CD11b + ) subsets and (C) representative results of flow cytometric analyses for MDSCs in the three groups of subjects. The number of cells in EGC, HE and HY in P2 were 8,394, 8,004 and 8,224, respectively. (D) The proportion of MDSCs in the three groups of subjects. (E) The proportion of MDSCs in peripheral whole blood derived from patients with early (n=13) or advanced (n=26) gastric cancer. The association between the proportion of MDSCs and (F) Th22, (G) Th17 and (H) Th1 cells in peripheral whole blood of elderly patients with cancer. *P